Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nalmefene and Coaching for Opioid and Alcohol Use Disorders
NCT03279562Phase 1Completed
- Sponsor
- Yale University
- Start
- Sep 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nalmefene in opioid use disorder (OUD) and alcohol use disorder (AUD), sponsored by Yale University. Primary endpoint: Duration of abstinence from illicit opioids at 30 days. Started Sep 2017; status: completed.
02
Drugs
nalmefene
03
Conditions
opioid use disorder (OUD)alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03279562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279562.